Locally advanced non-small cell lung cancer: What is the optimal concurrent chemoradiation regimen?

Cleveland Clinic Journal of Medicine

Volumn 79, Issue ELECTRONICSUPPL.1, 2012, Pages 32-37

  Videtic, Gregory M M ^a  

^a TAUSSIG CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT;

BIOLOGICAL THERAPY; CHEMORADIOTHERAPY; CONSOLIDATION CHEMOTHERAPY; HUMAN; INDUCTION CHEMOTHERAPY; LUNG NON SMALL CELL CANCER; LUNG TUMOR; METHODOLOGY; MORTALITY; PROGNOSIS; REVIEW; SURVIVAL RATE; TREATMENT OUTCOME;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOLOGICAL THERAPY; CARCINOMA, NON-SMALL-CELL LUNG; CHEMORADIOTHERAPY; CONSOLIDATION CHEMOTHERAPY; HUMANS; INDUCTION CHEMOTHERAPY; LUNG NEOPLASMS; PROGNOSIS; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 84866752964     PISSN: 08911150     EISSN: None     Source Type: Journal    
DOI: 10.3949/ccjm.79.s2.07     Document Type: Article

References (19)

1. Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A, eds. AJCC Cancer Staging Handbook. 7th ed. New York, NY:Springer; 2010:297-330.
2. Dillman RO, Seagren SL, Propert KJ, et al. A randomized trial of induction chemotherapy plus high-dose radiation versus radiation alone in stage III non-small-cell lung cancer. N Engl J Med 1990; 323:940-945.
3. Dillman RO, Herndon J, Seagren SL, Eaton WL, Green MR. Improved survival in stage III non-small-cell lung cancer: sevenyear follow-up of Cancer and Leukemia Group B (CALGB) 8433 trial. J Natl Cancer Inst 1996; 88:1210-1215.
4. Sause WT, Scott C, Taylor S, et al. Radiation Therapy Oncology Group (RTOG) 88-08 and Eastern Cooperative Oncology Group (ECOG) 4588: preliminary results of a phase III trial in regionally advanced, unresectable non-small-cell lung cancer. J Natl Cancer Inst 1995; 87:198-205.
5. Sause W, Kolesar P, Taylor S IV, et al. Final results of phase III trial in regionally advanced, unresectable non-small-cell lung cancer*:Radiation Therapy Oncology Group, Eastern Cooperative Oncology Group, and Southwest Oncology Group. Chest 2000; 117:358-364.
6. Bayman NA, Blackhall F, Jain P, et al. Management of unresectable stage III non-small-cell lung cancer with combined-modality therapy: a review of the current literature and recommendations for treatment. Clin Lung Cancer 2008; 9:92-101.
7. Rowell NP, O'Rourke NP. Concurrent chemoradiotherapy in non-small cell lung cancer. Cochrane Database Syst Rev 2004; 18:CD002140.
8. Aupérin A, Le Pechoux C, Rolland E, et al. Meta-analysis of concomitant versus sequential radiochemotheapy in locally advanced non-small-cell lung cancer. J Clin Oncol 2010; 28:2181-2190.
9. Machtay M, Swann S, Komaki R, et al. Higher BED is associated with improved local-regional control and survival for NSCLC treated with chemoradiotherapy [ASTRO abstract]. Int J Radiat Oncol Biol Phys 2005; 63(suppl 1):S40.
10. Blumenschein GR Jr, Paulus R, Curran WJ, et al. A phase II study of cetuximab (C225) in combination with chemoradiation (CRT) in patients (PTS) with stage IIIA/B non-small cell lung cancer (NSCLC): a report of the 2 year and median survival (MS) for the RTOG 0324 trial. J Clin Oncol 2008; 26(suppl). Abstract 7516.
11. Riesterer O, Milas L, Ang KK. Use of molecular biomarkers for predicting the response to radiotherapy with or without chemotherapy. J Clin Oncol 2007; 26:4075-4083.
12. Mak RH, Doran E, Muzikansky A, et al. Thoracic radiation therapy in locally advanced NSCLC patients (pts) with EGFR mutations. J Clin Oncol 2010; 28(suppl). Abstract 7016.
13. Vokes EE, Herndon II JE, Kelley MJ, et al. Induction chemotherapy followed by chemoradiotherapy compared with chemoradiotherapy alone for regionally advanced unresectable stage III non-small-cell lung cancer: Cancer and Leukemia Group B. J Clin Oncol 2007; 25:1698-1704.
14. Belani CP, Choy H, Bonomi P, et al. Combined chemoradiotherapy regimens of paclitaxel and carboplatin for locally advanced non-small-cell lung cancer: a randomized phase II locally advanced multi-modality protocol. J Clin Oncol 2005; 23:5883-5891.
15. Gandara DR, Chansky K, Gaspar LE, Albain KS, Lara PN, Crowley J. Long term survival in stage IIIb non-small cell lung cancer (NSCLC) treated with consolidation docetaxel following concurrent chemoradiotherapy (SWOG S9504). J Clin Oncol 2005; 23(suppl). Abstract 7059.
16. Hanna N, Neubauer M, Yiannoutsos C, et al. Phase III study of cisplatin, etoposide, and concurrent chest radiation with or without consolidation docetaxel in patients with inoperable stage III non-small-cell lung cancer: the Hoosier Oncology Group and U.S. Oncology. J Clin Oncol 2008; 35:5755-5760.
17. Albain KS, Crowley JJ, Turrisi III AT, et al. Concurrent cisplatin, etoposide, and chest radiotherapy in pathologic stage IIIB nonsmall- cell lung cancer: a Southwest Oncology Group phase II study, SWOG 9019. J Clin Oncol 2002; 20:3454-3460.
18. Schiller JH, Dahlberg SE, Mehta M, et al. A phase III trial of carboplatin, paclitaxel, and thoracic radiation therapy with or without thalidomide in patients with stage III non-small cell carcinoma of the lung (NSCLC): E3598. J Clin Oncol 2009; 27(suppl). Abstract 7503.
19. Govindan R, Bogart J, Wang X, et al. Phase II study of pemetrexed, carboplatin, and thoracic radiation with or without cetuximab in patients with locally advanced unresectable non-small cell lung cancer: CALGB 30407. J Clin Oncol 2009; 27(suppl). Abstract 7505.